US6207646B1
(en)
|
1994-07-15 |
2001-03-27 |
University Of Iowa Research Foundation |
Immunostimulatory nucleic acid molecules
|
ATE355375T1
(de)
|
1996-01-04 |
2006-03-15 |
Novartis Vaccines & Diagnostic |
Bakterioferritin aus helicobacter pylori
|
US6406705B1
(en)
|
1997-03-10 |
2002-06-18 |
University Of Iowa Research Foundation |
Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
|
IL139813A0
(en)
|
1998-05-22 |
2002-02-10 |
Loeb Health Res Inst At The Ot |
Methods and products for inducing mucosal immunity
|
EP1666060A1
(en)
*
|
1998-10-16 |
2006-06-07 |
Glaxosmithkline Biologicals S.A. |
Adjuvant systems and vaccines
|
US20020061848A1
(en)
*
|
2000-07-20 |
2002-05-23 |
Ajay Bhatia |
Compounds and methods for treatment and diagnosis of chlamydial infection
|
GB9915204D0
(en)
*
|
1999-06-29 |
1999-09-01 |
Smithkline Beecham Biolog |
Vaccine
|
US20050002958A1
(en)
*
|
1999-06-29 |
2005-01-06 |
Smithkline Beecham Biologicals Sa |
Vaccines
|
ES2250151T3
(es)
*
|
1999-06-29 |
2006-04-16 |
Glaxosmithkline Biologicals S.A. |
Uso de cpg como adyuvante de vacuna contra vih.
|
GB9921146D0
(en)
|
1999-09-07 |
1999-11-10 |
Smithkline Beecham Biolog |
Novel composition
|
GB0025170D0
(en)
*
|
2000-10-13 |
2000-11-29 |
Smithkline Beecham Biolog |
Novel compounds
|
ES2330083T3
(es)
|
2000-10-27 |
2009-12-04 |
Novartis Vaccines And Diagnostics S.R.L. |
Acidos nucleicos y proteinas de estreptococos de los grupos a y b.
|
EP2336368A1
(en)
|
2000-12-07 |
2011-06-22 |
Novartis Vaccines and Diagnostics, Inc. |
Endogenous retroviruses up-regulated in prostate cancer
|
AU2002248392A1
(en)
*
|
2001-01-26 |
2002-08-06 |
Walter Reed Army Institute Of Research |
Recombinant plasmodium falciparum merozoite protein-1/42 vaccine
|
US7306806B2
(en)
|
2001-01-26 |
2007-12-11 |
United States Of America As Represented By The Secretary Of The Army |
Recombinant P. falciparum merozoite protein-142 vaccine
|
GB0115176D0
(en)
|
2001-06-20 |
2001-08-15 |
Chiron Spa |
Capular polysaccharide solubilisation and combination vaccines
|
US8481043B2
(en)
|
2001-06-22 |
2013-07-09 |
Cpex Pharmaceuticals, Inc. |
Nasal immunization
|
SK15762003A3
(sk)
|
2001-06-29 |
2005-01-03 |
Chiron Corporation |
Kompozícia vakcíny HCV E1E2
|
GB0118249D0
(en)
|
2001-07-26 |
2001-09-19 |
Chiron Spa |
Histidine vaccines
|
GB0121591D0
(en)
|
2001-09-06 |
2001-10-24 |
Chiron Spa |
Hybrid and tandem expression of neisserial proteins
|
AR045702A1
(es)
|
2001-10-03 |
2005-11-09 |
Chiron Corp |
Composiciones de adyuvantes.
|
US7501134B2
(en)
|
2002-02-20 |
2009-03-10 |
Novartis Vaccines And Diagnostics, Inc. |
Microparticles with adsorbed polypeptide-containing molecules
|
GB0206360D0
(en)
|
2002-03-18 |
2002-05-01 |
Glaxosmithkline Biolog Sa |
Viral antigens
|
ATE545651T1
(de)
|
2002-06-13 |
2012-03-15 |
Novartis Vaccines & Diagnostic |
Vektoren zur expression von hml-2-polypeptiden
|
JP2005533855A
(ja)
|
2002-07-24 |
2005-11-10 |
インターツェル・アクチェンゲゼルシャフト |
病原性ウイルスからの別のリーディングフレームによりコードされる抗原
|
GB0220194D0
(en)
|
2002-08-30 |
2002-10-09 |
Chiron Spa |
Improved vesicles
|
EP1537418A2
(en)
|
2002-09-13 |
2005-06-08 |
Intercell AG |
Method for isolating hepatitis c virus peptides
|
DE60335477D1
(de)
|
2002-10-11 |
2011-02-03 |
Novartis Vaccines & Diagnostic |
Polypeptidimpstoffe zum breiten schutz gegen hypervirulente meningokokken-linien
|
US20070059329A1
(en)
|
2002-11-15 |
2007-03-15 |
Nathalie Norais |
Unexpected surface proteins in meningococcus
|
GB0227346D0
(en)
|
2002-11-22 |
2002-12-31 |
Chiron Spa |
741
|
WO2004053104A2
(en)
|
2002-12-11 |
2004-06-24 |
Coley Pharmaceutical Group, Inc. |
5’ cpg nucleic acids and methods of use
|
US7858098B2
(en)
|
2002-12-20 |
2010-12-28 |
Glaxosmithkline Biologicals, S.A. |
Vaccine
|
JP2006520746A
(ja)
*
|
2002-12-27 |
2006-09-14 |
カイロン コーポレイション |
リン脂質を含む免疫原性組成物
|
KR100692203B1
(ko)
*
|
2003-01-23 |
2007-03-09 |
제일모직주식회사 |
도광판, 이의 제조 방법, 이를 이용한 백라이트 어셈블리및 이를 이용한 액정표시장치
|
EP2191844B1
(en)
|
2003-01-30 |
2014-03-05 |
Novartis AG |
Injectable vaccines against multiple meningococcal serogroups
|
DE602004029657D1
(de)
|
2003-03-24 |
2010-12-02 |
Intercell Ag |
Verbesserte impfstoffe
|
JP2006521321A
(ja)
*
|
2003-03-24 |
2006-09-21 |
インターツェル・アクチェンゲゼルシャフト |
免疫応答を促進するためのミョウバンおよびTh1免疫応答誘起アジュバントの使用
|
CA2520124A1
(en)
|
2003-03-28 |
2004-10-14 |
Chiron Corporation |
Use of benzazole compounds for immunopotentiation
|
GB0308198D0
(en)
|
2003-04-09 |
2003-05-14 |
Chiron Srl |
ADP-ribosylating bacterial toxin
|
FR2854803B1
(fr)
*
|
2003-05-16 |
2005-06-24 |
Aventis Pasteur |
Composition vaccinale comprenant du phosphate de fer a titre d'adjuvent vaccinal.
|
WO2005020964A1
(en)
|
2003-06-02 |
2005-03-10 |
Chiron Corporation |
Immunogenic compositions based on microparticles comprising adsorbed toxoid and a polysaccharide-containing antigen
|
CA2532369C
(en)
|
2003-07-31 |
2016-07-26 |
Chiron Corporation |
Immunogenic compositions for streptococcus pyogenes
|
US20060035242A1
(en)
|
2004-08-13 |
2006-02-16 |
Michelitsch Melissa D |
Prion-specific peptide reagents
|
DE202005022108U1
(de)
|
2004-03-09 |
2013-11-12 |
Novartis Vaccines And Diagnostics, Inc. |
Influenza-Virus-Impfstoffe
|
PL1740217T3
(pl)
|
2004-04-30 |
2012-03-30 |
Novartis Ag |
Szczepienie koniugatem meningokokowym
|
GB0409745D0
(en)
|
2004-04-30 |
2004-06-09 |
Chiron Srl |
Compositions including unconjugated carrier proteins
|
GB0500787D0
(en)
|
2005-01-14 |
2005-02-23 |
Chiron Srl |
Integration of meningococcal conjugate vaccination
|
GB0410866D0
(en)
|
2004-05-14 |
2004-06-16 |
Chiron Srl |
Haemophilius influenzae
|
EP2848692B1
(en)
|
2004-05-21 |
2017-08-16 |
Novartis Vaccines and Diagnostics, Inc. |
Alphavirus vectors for influenza virus vaccines
|
US7758866B2
(en)
|
2004-06-16 |
2010-07-20 |
Glaxosmithkline Biologicals, S.A. |
Vaccine against HPV16 and HPV18 and at least another HPV type selected from HPV 31, 45 or 52
|
JP2008504292A
(ja)
|
2004-06-24 |
2008-02-14 |
ノバルティス ヴァクシンズ アンド ダイアグノスティクス, インコーポレイテッド |
免疫増強用の化合物
|
EP1784211A4
(en)
|
2004-07-29 |
2010-06-30 |
Novartis Vaccines & Diagnostic |
IMMUNOGENIC COMPOSITIONS FOR GRAMPOSITIVE BACTERIA SUCH AS STREPTOCOCCUS AGALACTIAE
|
GB0424092D0
(en)
|
2004-10-29 |
2004-12-01 |
Chiron Srl |
Immunogenic bacterial vesicles with outer membrane proteins
|
EP2682126B1
(en)
|
2005-01-27 |
2016-11-23 |
Children's Hospital & Research Center at Oakland |
GNA1870-based vesicle vaccines for broad spectrum protection against diseases caused by Neisseria meningitidis
|
GB0502095D0
(en)
|
2005-02-01 |
2005-03-09 |
Chiron Srl |
Conjugation of streptococcal capsular saccharides
|
CN101146551A
(zh)
*
|
2005-02-16 |
2008-03-19 |
诺华疫苗和诊断公司 |
含有磷酸铝和3d-mpl的佐剂组合物
|
ES2569654T3
(es)
|
2005-02-18 |
2016-05-12 |
Glaxosmithkline Biologicals Sa |
Proteínas y ácidos nucleicos de la meningitis / sepsis asociada a la Escherichia coli
|
CN102675432A
(zh)
|
2005-02-18 |
2012-09-19 |
诺华疫苗和诊断公司 |
来自尿路病原性大肠杆菌的免疫原
|
AU2006274647B2
(en)
*
|
2005-08-02 |
2013-01-10 |
Novartis Vaccines And Diagnostics Srl |
Reducing interference between oil-containing adjuvants and surfactant-containing antigens
|
CA2626253A1
(en)
|
2005-10-18 |
2007-04-26 |
Novartis Vaccines And Diagnostics, Inc. |
Mucosal and systemic immunizations with alphavirus replicon particles
|
US11707520B2
(en)
|
2005-11-03 |
2023-07-25 |
Seqirus UK Limited |
Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture
|
WO2007052061A2
(en)
*
|
2005-11-04 |
2007-05-10 |
Novartis Vaccines And Diagnostics Srl |
Emulsions with free aqueous-phase surfactant as adjuvants for split influenza vaccines
|
JP2009514838A
(ja)
|
2005-11-04 |
2009-04-09 |
ノバルティス ヴァクシンズ アンド ダイアグノスティクス エスアールエル |
細胞培養物において増殖されたインフルエンザウイルスから調製された非ビリオン抗原を含むアジュバントワクチン
|
AU2006335256B2
(en)
|
2005-11-22 |
2012-10-18 |
Novartis Vaccines And Diagnostics, Inc. |
Norovirus and sapovirus antigens
|
GB0524066D0
(en)
|
2005-11-25 |
2006-01-04 |
Chiron Srl |
741 ii
|
WO2007070660A2
(en)
|
2005-12-13 |
2007-06-21 |
President And Fellows Of Harvard College |
Scaffolds for cell transplantation
|
GB0607088D0
(en)
|
2006-04-07 |
2006-05-17 |
Glaxosmithkline Biolog Sa |
Vaccine
|
DK2384765T3
(en)
|
2005-12-22 |
2017-01-09 |
Glaxosmithkline Biologicals Sa |
Vaccine against Streptococcus pneumoniae.
|
EA015271B1
(ru)
|
2006-01-27 |
2011-06-30 |
Новартис Вэксинс Энд Диагностикс Гмбх & Ко Кг |
Противогриппозные вакцины, содержащие гемагглютинин и белки матрикса
|
EP2357184B1
(en)
|
2006-03-23 |
2015-02-25 |
Novartis AG |
Imidazoquinoxaline compounds as immunomodulators
|
EP2004226A1
(en)
|
2006-03-24 |
2008-12-24 |
Novartis Vaccines and Diagnostics GmbH & Co. KG |
Storage of influenza vaccines without refrigeration
|
EP3141261A1
(en)
|
2006-03-30 |
2017-03-15 |
GlaxoSmithKline Biologicals S.A. |
Immunogenic composition
|
EP2382988A1
(en)
|
2006-03-31 |
2011-11-02 |
Novartis AG |
Combined mucosal and parenteral immunization against HIV
|
CN1864749B
(zh)
*
|
2006-04-12 |
2010-10-06 |
成都夸常医学工业有限公司 |
一种药物组合物及制备方法
|
US9839685B2
(en)
*
|
2006-04-13 |
2017-12-12 |
The Regents Of The University Of Michigan |
Methods of inducing human immunodeficiency virus-specific immune responses in a host comprising nasally administering compositions comprising a naonemulsion and recombinant GP120 immunogen
|
CN101479293A
(zh)
|
2006-06-29 |
2009-07-08 |
诺华有限公司 |
脑膜炎奈瑟球菌多肽
|
GB0614460D0
(en)
|
2006-07-20 |
2006-08-30 |
Novartis Ag |
Vaccines
|
EP2064230A2
(en)
|
2006-08-16 |
2009-06-03 |
Novartis AG |
Immunogens from uropathogenic escherichia coli
|
CA3016948A1
(en)
|
2006-09-11 |
2008-03-20 |
Seqirus UK Limited |
Making influenza virus vaccines without using eggs
|
US8080645B2
(en)
*
|
2007-10-01 |
2011-12-20 |
Longhorn Vaccines & Diagnostics Llc |
Biological specimen collection/transport compositions and methods
|
US8652782B2
(en)
|
2006-09-12 |
2014-02-18 |
Longhorn Vaccines & Diagnostics, Llc |
Compositions and methods for detecting, identifying and quantitating mycobacterial-specific nucleic acids
|
US9481912B2
(en)
|
2006-09-12 |
2016-11-01 |
Longhorn Vaccines And Diagnostics, Llc |
Compositions and methods for detecting and identifying nucleic acid sequences in biological samples
|
US8097419B2
(en)
|
2006-09-12 |
2012-01-17 |
Longhorn Vaccines & Diagnostics Llc |
Compositions and method for rapid, real-time detection of influenza A virus (H1N1) swine 2009
|
US20090181078A1
(en)
*
|
2006-09-26 |
2009-07-16 |
Infectious Disease Research Institute |
Vaccine composition containing synthetic adjuvant
|
PL2484375T3
(pl)
|
2006-09-26 |
2018-09-28 |
Infectious Disease Research Institute |
Kompozycja szczepionki zawierająca syntetyczny adiuwant
|
EP2679240A1
(en)
|
2006-12-06 |
2014-01-01 |
Novartis AG |
Vaccines including antigen from four strains of influenza virus
|
GB0700562D0
(en)
|
2007-01-11 |
2007-02-21 |
Novartis Vaccines & Diagnostic |
Modified Saccharides
|
EA200901578A1
(ru)
|
2007-06-26 |
2010-08-30 |
Глаксосмитклайн Байолоджикалс С.А. |
Вакцина, содержащая конъюгаты капсульных полисахаридов streptococcus pneumoniae
|
EA201070066A1
(ru)
|
2007-06-27 |
2010-06-30 |
Новартис Аг |
Вакцины против гриппа с низким содержанием добавок
|
GB0713880D0
(en)
|
2007-07-17 |
2007-08-29 |
Novartis Ag |
Conjugate purification
|
GB0714963D0
(en)
|
2007-08-01 |
2007-09-12 |
Novartis Ag |
Compositions comprising antigens
|
US9683256B2
(en)
|
2007-10-01 |
2017-06-20 |
Longhorn Vaccines And Diagnostics, Llc |
Biological specimen collection and transport system
|
US11041215B2
(en)
|
2007-08-24 |
2021-06-22 |
Longhorn Vaccines And Diagnostics, Llc |
PCR ready compositions and methods for detecting and identifying nucleic acid sequences
|
CA2976814C
(en)
|
2007-08-27 |
2022-12-13 |
Longhorn Vaccines & Diagnostics, Llc |
Immunogenic compositions and methods for treating influenza
|
US10004799B2
(en)
|
2007-08-27 |
2018-06-26 |
Longhorn Vaccines And Diagnostics, Llc |
Composite antigenic sequences and vaccines
|
ES2552858T3
(es)
|
2007-10-01 |
2015-12-02 |
Longhorn Vaccines And Diagnostics, Llc |
Recogida de muestras biológicas y sistema de transporte y métodos de uso
|
US11041216B2
(en)
|
2007-10-01 |
2021-06-22 |
Longhorn Vaccines And Diagnostics, Llc |
Compositions and methods for detecting and quantifying nucleic acid sequences in blood samples
|
GB0810305D0
(en)
|
2008-06-05 |
2008-07-09 |
Novartis Ag |
Influenza vaccination
|
GB0818453D0
(en)
|
2008-10-08 |
2008-11-12 |
Novartis Ag |
Fermentation processes for cultivating streptococci and purification processes for obtaining cps therefrom
|
DK2235046T3
(da)
|
2007-12-21 |
2012-10-29 |
Novartis Ag |
Mutante former af streptolysin-O
|
HUE029258T2
(en)
*
|
2007-12-24 |
2017-02-28 |
Id Biomedical Corp Quebec |
Recombinant rsv antigens
|
RU2475496C2
(ru)
|
2008-02-21 |
2013-02-20 |
Новартис Аг |
МЕНИНГОКОККОВЫЕ ПОЛИПЕПТИДЫ fHBP
|
EP2265640B1
(en)
|
2008-03-10 |
2015-11-04 |
Children's Hospital & Research Center at Oakland |
Chimeric factor h binding proteins (fhbp) containing a heterologous b domain and methods of use
|
EA201071086A1
(ru)
|
2008-03-18 |
2011-04-29 |
Новартис Аг |
Усовершенствованный способ получения вакцинных антигенов вируса гриппа
|
AU2009248810B2
(en)
|
2008-05-23 |
2013-12-05 |
The Regents Of The University Of Michigan |
Nanoemulsion vaccines
|
EP2280728B1
(en)
*
|
2008-05-26 |
2016-03-02 |
Cadila Healthcare Limited |
Combined measles-human papilloma vaccine
|
US9114098B2
(en)
|
2008-06-04 |
2015-08-25 |
The Chemo-Sero-Therapeutic Research Institute |
Method for using inactivated Japanese encephalitis virus particles as adjuvant
|
EA201170217A1
(ru)
*
|
2008-07-18 |
2011-08-30 |
АйДи БАЙОМЕДИКАЛ КОРПОРЕЙШН ОФ КВЕБЕК |
Гибридные полипептидные антигены респираторно-синцитиального вируса
|
GB0815872D0
(en)
|
2008-09-01 |
2008-10-08 |
Pasteur Institut |
Novel method and compositions
|
KR101634058B1
(ko)
|
2008-12-09 |
2016-06-27 |
화이자 백신스 엘엘씨 |
IgE CH3 펩티드 백신
|
US8585505B2
(en)
|
2008-12-15 |
2013-11-19 |
Tetris Online, Inc. |
Inter-game interactive hybrid asynchronous computer game infrastructure
|
PL2396032T3
(pl)
|
2009-02-10 |
2017-05-31 |
Seqirus UK Limited |
Szczepionki przeciw grypie o obniżonych zawartościach skwalenu
|
SG173194A1
(en)
*
|
2009-02-17 |
2011-09-29 |
Glaxosmithkline Biolog Sa |
Inactivated dengue virus vaccine with aluminium-free adjuvant
|
ES2671880T3
(es)
*
|
2009-03-05 |
2018-06-11 |
Jenny Colleen Mccloskey |
Tratamiento de infección
|
RU2011140508A
(ru)
|
2009-03-06 |
2013-04-20 |
Новартис Аг |
Антигены хламидии
|
CA2758490C
(en)
|
2009-04-14 |
2023-05-02 |
Novartis Ag |
Compositions for immunising against staphylococcus aureus
|
US8574589B2
(en)
|
2009-05-11 |
2013-11-05 |
Novartis Ag |
Antigen purification process for pertactin antigen
|
WO2010141861A1
(en)
|
2009-06-05 |
2010-12-09 |
Infectious Disease Research Institute |
Synthetic glucopyranosyl lipid adjuvants
|
EP2442826B1
(en)
|
2009-06-15 |
2015-07-08 |
National University of Singapore |
Influenza vaccine, composition, and methods of use
|
BRPI1014031A2
(pt)
*
|
2009-06-16 |
2018-02-20 |
Univ Michigan Regents |
vacinas de nanoemulsão
|
PL2445526T3
(pl)
|
2009-06-24 |
2017-08-31 |
Glaxosmithkline Biologicals S.A. |
Rekombinowane antygeny rsv
|
JP5796011B2
(ja)
|
2009-06-24 |
2015-10-21 |
グラクソスミスクライン バイオロジカルズ ソシエテ アノニム |
ワクチン
|
MA33440B1
(fr)
|
2009-06-25 |
2012-07-03 |
Glaxosmithkline Biolog Sa |
Nouvelles compositions
|
CN102666571A
(zh)
|
2009-07-07 |
2012-09-12 |
诺华有限公司 |
保守的大肠杆菌免疫原
|
EP4183412B1
(en)
|
2009-07-15 |
2024-08-14 |
GlaxoSmithKline Biologicals SA |
Rsv f protein compositions and methods for making same
|
CA2768343A1
(en)
|
2009-07-16 |
2011-01-20 |
Novartis Ag |
Detoxified escherichia coli immunogens
|
MX2012001194A
(es)
|
2009-07-30 |
2012-03-07 |
Pfizer Vaccines Llc |
Peptidos tau antigenicos y usos de los mismos.
|
GB0913680D0
(en)
|
2009-08-05 |
2009-09-16 |
Glaxosmithkline Biolog Sa |
Immunogenic composition
|
BR112012003977A2
(pt)
*
|
2009-08-26 |
2017-06-06 |
Selecta Biosciences Inc |
composições que induzem ajuda de célula t
|
NZ622048A
(en)
|
2009-08-27 |
2015-10-30 |
Novartis Ag |
Hybrid polypeptides including meningococcal fhbp sequences
|
PT2473605T
(pt)
|
2009-09-03 |
2018-05-28 |
Pfizer Vaccines Llc |
Vacina pcsk9
|
JP2013506651A
(ja)
|
2009-09-30 |
2013-02-28 |
ノバルティス アーゲー |
Staphylococcus.aureus5型および8型莢膜多糖の結合体
|
GB0918392D0
(en)
|
2009-10-20 |
2009-12-02 |
Novartis Ag |
Diagnostic and therapeutic methods
|
AU2010310985B2
(en)
|
2009-10-27 |
2014-11-06 |
Glaxosmithkline Biologicals S.A. |
Modified meningococcal fHBP polypeptides
|
GB0919690D0
(en)
|
2009-11-10 |
2009-12-23 |
Guy S And St Thomas S Nhs Foun |
compositions for immunising against staphylococcus aureus
|
CN102762224A
(zh)
|
2009-12-22 |
2012-10-31 |
塞尔德克斯医疗公司 |
疫苗组合物
|
PL2528621T3
(pl)
|
2010-01-27 |
2017-07-31 |
Glaxosmithkline Biologicals S.A. |
Zmodyfikowane antygeny gruźlicy
|
ES2661569T3
(es)
|
2010-03-30 |
2018-04-02 |
Children's Hospital & Research Center At Oakland |
Proteínas de unión al factor H (fHbp) con propiedades alteradas y métodos de uso de las mismas
|
US9597326B2
(en)
|
2010-04-13 |
2017-03-21 |
Glaxosmithkline Biologicals Sa |
Benzonapthyridine compositions and uses thereof
|
CA2798994A1
(en)
|
2010-05-26 |
2011-12-01 |
Selecta Biosciences, Inc. |
Multivalent synthetic nanocarrier vaccines
|
WO2011148382A1
(en)
|
2010-05-28 |
2011-12-01 |
Biological E Limited |
An improved process for the purification of capsular polysaccharides of haemophilus influenza - b, neisseria meningitis such as serotypes a, c, y and w-135, and other similar related capsular polysaccharides produced from both gram negative and gram positive microorganisms using aluminium phosphate with alcohol.
|
CA2798837A1
(en)
|
2010-06-07 |
2011-12-15 |
Pfizer Inc. |
Her-2 peptides and vaccines
|
WO2011154878A1
(en)
|
2010-06-07 |
2011-12-15 |
Pfizer Vaccines Llc |
Ige ch3 peptide vaccine
|
GB201009861D0
(en)
|
2010-06-11 |
2010-07-21 |
Novartis Ag |
OMV vaccines
|
US9192661B2
(en)
|
2010-07-06 |
2015-11-24 |
Novartis Ag |
Delivery of self-replicating RNA using biodegradable polymer particles
|
WO2012006293A1
(en)
|
2010-07-06 |
2012-01-12 |
Novartis Ag |
Norovirus derived immunogenic compositions and methods
|
GB201101665D0
(en)
|
2011-01-31 |
2011-03-16 |
Novartis Ag |
Immunogenic compositions
|
CN102441162B
(zh)
*
|
2010-10-04 |
2018-07-24 |
免疫产品美国股份有限公司 |
结核病的治疗和预防
|
EA201390660A1
(ru)
|
2010-11-05 |
2013-11-29 |
Селекта Байосайенсиз, Инк. |
Модифицированные никотиновые соединения и связанные способы
|
WO2012085668A2
(en)
|
2010-12-24 |
2012-06-28 |
Novartis Ag |
Compounds
|
ES3018416T3
(es)
|
2011-01-26 |
2025-05-16 |
Glaxosmithkline Biologicals Sa |
Régimen de inmunización del VRS
|
EP2680883B1
(en)
|
2011-03-02 |
2018-09-05 |
Pfizer Inc |
Pcsk9 vaccine
|
JP5798356B2
(ja)
*
|
2011-04-06 |
2015-10-21 |
一般財団法人化学及血清療法研究所 |
新規インフルエンザワクチン安定化剤
|
MX350795B
(es)
|
2011-04-08 |
2017-09-19 |
Inmune Design Corp |
Composiciones inmunogenicas y metodos para utilizar las composiciones para inducir respuestas inmunes humorales y celulares.
|
US9675561B2
(en)
|
2011-04-28 |
2017-06-13 |
President And Fellows Of Harvard College |
Injectable cryogel vaccine devices and methods of use thereof
|
DK2707385T3
(da)
|
2011-05-13 |
2017-11-20 |
Glaxosmithkline Biologicals Sa |
RSV-F-præfusionsantigener
|
AU2012279154A1
(en)
*
|
2011-07-01 |
2014-02-20 |
The Regents Of The University Of California |
Herpes virus vaccine and methods of use
|
EP2729165B1
(en)
|
2011-07-06 |
2017-11-08 |
GlaxoSmithKline Biologicals SA |
Immunogenic combination compositions and uses thereof
|
JP2014520807A
(ja)
|
2011-07-06 |
2014-08-25 |
ノバルティス アーゲー |
免疫原性組成物およびその使用
|
FR2977800B1
(fr)
|
2011-07-13 |
2014-03-14 |
Sanofi Pasteur |
Composition vaccinale avec des nanoparticules d'hydroxyde d'aluminium
|
US20130028857A1
(en)
|
2011-07-29 |
2013-01-31 |
Selecta Biosciences, Inc. |
Synthetic nanocarriers comprising polymers comprising multiple immunomodulatory agents
|
JP6205360B2
(ja)
|
2011-08-22 |
2017-09-27 |
ナノバイオ コーポレーション |
単純ヘルペスウイルスのナノエマルジョンワクチン
|
CA2848163C
(en)
|
2011-09-09 |
2020-10-27 |
Nanobio Corporation |
Nanoemulsion respiratory syncytial virus (rsv) subunit vaccine
|
EP2755684A1
(en)
|
2011-09-12 |
2014-07-23 |
Jonathan Norden Weber |
Methods and compositions for raising an immune response to hiv
|
US20150044251A1
(en)
|
2011-12-23 |
2015-02-12 |
Novartis Ag |
Stable compositions for immunising against staphylococcus aureus
|
CA3207612A1
(en)
|
2012-01-26 |
2013-08-01 |
Longhorn Vaccines And Diagnostics, Llc |
Composite antigenic sequences and vaccines
|
WO2013139744A1
(en)
|
2012-03-18 |
2013-09-26 |
Glaxosmithkline Biologicals S.A. |
Method of vaccination against human papillomavirus
|
WO2013158673A1
(en)
*
|
2012-04-16 |
2013-10-24 |
President And Fellows Of Harvard College |
Mesoporous silica compositions for modulating immune responses
|
EP2659906A1
(en)
*
|
2012-05-01 |
2013-11-06 |
Affiris AG |
Compositions
|
EP2659907A1
(en)
*
|
2012-05-01 |
2013-11-06 |
Affiris AG |
Compositions
|
JP6619648B2
(ja)
|
2012-05-16 |
2019-12-11 |
イミューン デザイン コーポレイション |
Hsv−2のためのワクチン
|
SG10201608675YA
(en)
|
2012-05-22 |
2016-12-29 |
Novartis Ag |
Meningococcus serogroup x conjugate
|
CN104853770A
(zh)
|
2012-07-06 |
2015-08-19 |
诺华股份有限公司 |
免疫原性组合物及其应用
|
US20150203543A1
(en)
|
2012-08-31 |
2015-07-23 |
Novartis Ag |
Stabilised proteins for immunising against staphylococcus aureus
|
SI2890394T1
(sl)
|
2012-08-31 |
2019-06-28 |
Glaxosmithkline Biologicals Sa |
Stabilizirani proteini za imunizacijo proti staphylococcusu aureusu
|
WO2014053521A2
(en)
|
2012-10-02 |
2014-04-10 |
Novartis Ag |
Nonlinear saccharide conjugates
|
EP2903638B1
(en)
|
2012-10-03 |
2019-12-18 |
GlaxoSmithKline Biologicals SA |
Immunogenic composition
|
PT2908857T
(pt)
*
|
2012-10-19 |
2017-09-11 |
Hal Allergy Holding B V |
Composições para imunoterapia
|
EP3345617B1
(en)
|
2012-11-30 |
2020-08-26 |
GlaxoSmithKline Biologicals S.A. |
Pseudomonas antigens and antigen combinations
|
WO2014172637A1
(en)
|
2013-04-18 |
2014-10-23 |
Immune Design Corp. |
Gla monotherapy for use in cancer treatment
|
JP2016520077A
(ja)
|
2013-05-15 |
2016-07-11 |
ザ ガバナーズ オブ ザ ユニバーシティ オブ アルバータ |
E1e2hcvワクチン及び使用方法
|
US9463198B2
(en)
|
2013-06-04 |
2016-10-11 |
Infectious Disease Research Institute |
Compositions and methods for reducing or preventing metastasis
|
EP2870974A1
(en)
|
2013-11-08 |
2015-05-13 |
Novartis AG |
Salmonella conjugate vaccines
|
US11160855B2
(en)
|
2014-01-21 |
2021-11-02 |
Pfizer Inc. |
Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
|
EP3616716A3
(en)
|
2014-01-21 |
2020-05-06 |
Pfizer Inc |
Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
|
EP3104877B1
(en)
|
2014-02-11 |
2020-01-22 |
The USA, as represented by The Secretary, Department of Health and Human Services |
Pcsk9 vaccine and methods of using the same
|
SG11201606887WA
(en)
|
2014-03-26 |
2016-09-29 |
Glaxosmithkline Biolog Sa |
Mutant staphylococcal antigens
|
CN107073090A
(zh)
|
2014-04-30 |
2017-08-18 |
哈佛学院董事会 |
结合的疫苗装置和杀死癌细胞的方法
|
CA3212723A1
(en)
|
2014-07-23 |
2016-01-28 |
Peter T. Beernink |
Factor h binding protein variants and methods of use thereof
|
CN107427568B
(zh)
|
2015-01-15 |
2021-12-14 |
辉瑞公司 |
用于肺炎球菌疫苗中的免疫原性组合物
|
HK1247861A1
(zh)
|
2015-01-30 |
2018-10-05 |
President And Fellows Of Harvard College |
用於癌症治疗的肿瘤周围和肿瘤内部材料
|
US9976136B2
(en)
|
2015-05-14 |
2018-05-22 |
Longhorn Vaccines And Diagnostics, Llc |
Rapid methods for the extraction of nucleic acids from biological samples
|
JP2018521016A
(ja)
|
2015-06-03 |
2018-08-02 |
アフィリス・アクチェンゲゼルシャフトAffiris Ag |
IL−23−p19ワクチン
|
AU2016289497A1
(en)
|
2015-07-07 |
2017-12-07 |
Affiris Ag |
Vaccines for the treatment and prevention of IgE mediated diseases
|
TWI684461B
(zh)
|
2015-07-21 |
2020-02-11 |
美商輝瑞股份有限公司 |
包含經共軛之莢膜糖抗原的致免疫性組成物、包含該致免疫性組成物之套組及彼等之用途
|
WO2017033123A1
(en)
|
2015-08-25 |
2017-03-02 |
Babita Agrawal |
Immunomodulatory compositions and methods of use thereof
|
EP3359577A4
(en)
|
2015-10-08 |
2019-04-17 |
The Governors of the University of Alberta |
HEPATITIS C-VIRUS E1 / E2 HETERODIMERS AND METHOD FOR THE PRODUCTION THEREOF
|
US10786561B2
(en)
|
2015-11-20 |
2020-09-29 |
Pfizer Inc. |
Immunogenic compositions for use in pneumococcal vaccines
|
WO2017136837A1
(en)
|
2016-02-06 |
2017-08-10 |
President And Fellows Of Harvard College |
Recapitulating the hematopoietic niche to reconstitute immunity
|
DK3484448T3
(da)
|
2016-07-13 |
2025-06-10 |
Harvard College |
Antigenpræsenterende cellemimetiske stilladser og fremgangsmåder til fremstilling og brug af disse
|
JP7274214B2
(ja)
|
2016-08-02 |
2023-05-16 |
プレジデント アンド フェローズ オブ ハーバード カレッジ |
免疫応答を調節するための生体材料
|
WO2018060288A1
(en)
|
2016-09-29 |
2018-04-05 |
Glaxosmithkline Biologicals S.A. |
Compositions and methods of treatment of persistent hpv infection
|
WO2018097642A1
(ko)
*
|
2016-11-25 |
2018-05-31 |
재단법인 목암생명과학연구소 |
바리셀라 조스터 바이러스 백신
|
US10874734B2
(en)
|
2016-11-25 |
2020-12-29 |
Mogam Institute For Biomedical Research |
Varicella zoster virus vaccine
|
GB201620968D0
(en)
|
2016-12-09 |
2017-01-25 |
Glaxosmithkline Biologicals Sa |
Adenovirus polynucleotides and polypeptides
|
ES2911490T3
(es)
|
2017-01-20 |
2022-05-19 |
Pfizer |
Composiciones inmunogénicas para su uso en vacunas antineumocócicas
|
CN107537035A
(zh)
*
|
2017-08-30 |
2018-01-05 |
北京恩元华生物科技有限公司 |
复合佐剂及含复合佐剂的狂犬疫苗及其制备方法和应用
|
GB201721069D0
(en)
|
2017-12-15 |
2018-01-31 |
Glaxosmithkline Biologicals Sa |
Hepatitis B Immunisation regimen and compositions
|
GB201721068D0
(en)
|
2017-12-15 |
2018-01-31 |
Glaxosmithkline Biologicals Sa |
Hepatitis B immunisation regimen and compositions
|
TW201946650A
(zh)
|
2018-03-12 |
2019-12-16 |
美商詹森藥物公司 |
針對腹內感染之疫苗
|
BR112020024285A2
(pt)
|
2018-06-12 |
2021-03-02 |
Glaxosmithkline Biologicals S.A. |
polinucleotídeos e polipeptídeos de adenovírus
|
JP2021533162A
(ja)
|
2018-08-07 |
2021-12-02 |
グラクソスミスクライン バイオロジカルズ ソシエテ アノニム |
プロセス及びワクチン
|
US11260119B2
(en)
|
2018-08-24 |
2022-03-01 |
Pfizer Inc. |
Escherichia coli compositions and methods thereof
|
WO2020061129A1
(en)
|
2018-09-19 |
2020-03-26 |
President And Fellows Of Harvard College |
Compositions and methods for labeling and modulation of cells in vitro and in vivo
|
EP3876982A1
(en)
|
2018-11-06 |
2021-09-15 |
GlaxoSmithKline Biologicals S.A. |
Immunogenic compositions
|
CA3120922A1
(en)
|
2018-12-12 |
2020-06-18 |
Pfizer Inc. |
Immunogenic multiple hetero-antigen polysaccharide-protein conjugates and uses thereof
|
WO2020128012A1
(en)
|
2018-12-21 |
2020-06-25 |
Glaxosmithkline Biologicals Sa |
Methods of inducing an immune response
|
JP7239509B6
(ja)
|
2019-02-22 |
2023-03-28 |
ファイザー・インク |
細菌多糖類を精製するための方法
|
CA3132601A1
(en)
|
2019-03-05 |
2020-09-10 |
Glaxosmithkline Biologicals Sa |
Hepatitis b immunisation regimen and compositions
|
BR112021018258A2
(pt)
|
2019-03-18 |
2022-02-08 |
Glaxosmithkline Biologicals Sa |
Método e célula hospedeira recombinante para preparar um bioconjugado, bioconjugado, e, composição
|
PH12021552155A1
(en)
|
2019-03-18 |
2022-08-15 |
Glaxosmithkline Biologicals Sa |
Bioconjugates of e. coli o-antigen polysaccharides, methods of production thereof, and methods of use thereof
|
EP3952906A1
(en)
|
2019-04-10 |
2022-02-16 |
Pfizer Inc. |
Immunogenic compositions comprising conjugated capsular saccharide antigens, kits comprising the same and uses thereof
|
CN112138155B
(zh)
*
|
2019-06-28 |
2022-04-12 |
怡道生物科技(苏州)有限公司 |
一种复合佐剂系统及制备该佐剂的方法
|
IL291821A
(en)
|
2019-10-02 |
2022-06-01 |
Janssen Vaccines & Prevention Bv |
Staphylococcus peptides and methods of use
|
AU2020375214B2
(en)
|
2019-11-01 |
2024-02-08 |
Pfizer Inc. |
Escherichia coli compositions and methods thereof
|
CA3168108A1
(en)
|
2020-01-16 |
2021-07-22 |
Janssen Pharmaceuticals, Inc. |
Fimh mutant, compositions therewith and use thereof
|
US20220380769A1
(en)
|
2020-01-24 |
2022-12-01 |
Aim Immunotech Inc. |
Methods, compositions, and vaccines for treating a virus infection
|
IL295713A
(en)
|
2020-02-21 |
2022-10-01 |
Pfizer |
Isolation of saccharides
|
JP2023514697A
(ja)
|
2020-02-23 |
2023-04-07 |
ファイザー・インク |
大腸菌組成物およびその方法
|
EP4114848A4
(en)
|
2020-02-26 |
2024-04-03 |
Versitech Limited |
PD-1-BASED VACCINES AGAINST CORONAVIRUS INFECTION
|
CN111920946B
(zh)
*
|
2020-08-07 |
2021-05-28 |
合肥诺为尔基因科技服务有限公司 |
环二核苷酸修饰铝纳米粒疫苗佐剂-传递系统及基于其的SARS-CoV-2亚单位疫苗
|
KR20230043157A
(ko)
|
2020-09-17 |
2023-03-30 |
얀센 파마슈티칼즈, 인코포레이티드 |
다가 백신 조성물 및 이의 용도
|
US12403189B2
(en)
|
2020-10-20 |
2025-09-02 |
Longhorn Vaccines And Diagnostics, Llc |
Immunogenic antigens
|
TW202227467A
(zh)
|
2020-10-27 |
2022-07-16 |
美商輝瑞大藥廠 |
大腸桿菌組合物及其方法
|
US12138302B2
(en)
|
2020-10-27 |
2024-11-12 |
Pfizer Inc. |
Escherichia coli compositions and methods thereof
|
MX2023005221A
(es)
|
2020-11-04 |
2023-05-16 |
Pfizer |
Composiciones inmunogenicas para uso en vacunas neumococicas.
|
WO2022101745A2
(en)
|
2020-11-10 |
2022-05-19 |
Pfizer Inc. |
Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
|
US12357681B2
(en)
|
2020-12-23 |
2025-07-15 |
Pfizer Inc. |
E. coli FimH mutants and uses thereof
|
US11725028B2
(en)
|
2021-01-12 |
2023-08-15 |
Janssen Pharmaceuticals, Inc. |
FimH mutants, compositions therewith and use thereof
|
EP4291231A1
(en)
|
2021-02-11 |
2023-12-20 |
GlaxoSmithKline Biologicals S.A. |
Hpv vaccine manufacture
|
IT202100003470A1
(it)
|
2021-02-16 |
2022-08-16 |
Fond Toscana Life Sciences |
Vaccines against sars-cov-2
|
IL305313A
(en)
|
2021-02-19 |
2023-10-01 |
Sanofi Pasteur |
Meningococcal b recombinant vaccine
|
CN115120713A
(zh)
*
|
2021-03-25 |
2022-09-30 |
四川大学 |
氢氧化铝-CpG寡核苷酸-多肽复合佐剂、疫苗及制备方法和用途
|
US12290563B2
(en)
|
2021-04-01 |
2025-05-06 |
Janssen Pharmaceuticals, Inc. |
Production of E. coli 018 bioconjugates
|
EP4333868A1
(en)
|
2021-05-04 |
2024-03-13 |
King Abdullah University Of Science And Technology |
Immuogenic compositions of mutant sars-cov-2 n protein and gene and methods of use thereof
|
BR112023023671A2
(pt)
|
2021-05-28 |
2024-02-06 |
Pfizer |
Composições imunogênicas compreendendo antígenos de sacarídeo capsular conjugados e usos dos mesmos
|
WO2022249107A2
(en)
|
2021-05-28 |
2022-12-01 |
Pfizer Inc. |
Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
|
US20250049899A1
(en)
|
2021-11-18 |
2025-02-13 |
Matrivax, Inc. |
Immunogenic fusion protein compositions and methods of use thereof
|
KR20240128715A
(ko)
|
2022-01-13 |
2024-08-26 |
화이자 인코포레이티드 |
접합된 피막 사카라이드 항원을 포함하는 면역원성 조성물 및 그의 용도
|
WO2023161817A1
(en)
|
2022-02-25 |
2023-08-31 |
Pfizer Inc. |
Methods for incorporating azido groups in bacterial capsular polysaccharides
|
AU2023268745A1
(en)
|
2022-05-11 |
2024-11-07 |
Pfizer Inc. |
Process for producing of vaccine formulations with preservatives
|
WO2024018061A1
(en)
|
2022-07-22 |
2024-01-25 |
Institut National de la Santé et de la Recherche Médicale |
Use of bordetella strains for the treatment of chronic obstructive pulmonary disease
|
WO2024110827A1
(en)
|
2022-11-21 |
2024-05-30 |
Pfizer Inc. |
Methods for preparing conjugated capsular saccharide antigens and uses thereof
|
EP4622665A2
(en)
|
2022-11-22 |
2025-10-01 |
Pfizer Inc. |
Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
|
CN120513083A
(zh)
|
2022-12-01 |
2025-08-19 |
辉瑞大药厂 |
肺炎链球菌缀合物疫苗制剂
|
WO2024133160A1
(en)
|
2022-12-19 |
2024-06-27 |
Glaxosmithkline Biologicals Sa |
Hepatitis b compositions
|
WO2024166008A1
(en)
|
2023-02-10 |
2024-08-15 |
Pfizer Inc. |
Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
|
WO2024201324A2
(en)
|
2023-03-30 |
2024-10-03 |
Pfizer Inc. |
Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
|
WO2024214016A1
(en)
|
2023-04-14 |
2024-10-17 |
Pfizer Inc. |
Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
|
WO2024224266A1
(en)
|
2023-04-24 |
2024-10-31 |
Pfizer Inc. |
Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
|
WO2024241172A2
(en)
|
2023-05-19 |
2024-11-28 |
Glaxosmithkline Biologicals Sa |
Methods for eliciting an immune response to respiratory syncycial virus and streptococcus pneumoniae infection
|
WO2025028658A1
(ja)
*
|
2023-08-03 |
2025-02-06 |
国立大学法人東京農工大学 |
免疫増強剤及び免疫増強方法並びにタンパク質の凝集体及び/又は会合体の製造方法
|
WO2025133971A1
(en)
|
2023-12-23 |
2025-06-26 |
Pfizer Inc. |
Improved methods for producing bacterial capsular saccharide glycoconjugates
|
WO2025186660A1
(en)
|
2024-03-05 |
2025-09-12 |
Fondazione Toscana Life Sciences |
Mutated spike proteins as vaccines against sars-cov-2
|
WO2025186705A2
(en)
|
2024-03-06 |
2025-09-12 |
Pfizer Inc. |
Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
|
WO2025191415A1
(en)
|
2024-03-11 |
2025-09-18 |
Pfizer Inc. |
Immunogenic compositions comprising conjugated escherichia coli saccharides and uses thereof
|